Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of long-acting octreotide injection as adjuvant therapy after resection of pancreatic neuroendocrine tumor
CTR20254378Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in islet cell tumor comparing Octreotide long-acting injection with Placebo (2 arms). Primary endpoint: Disease-free survival by blinded independent central review. Started Jan 2026; status: active.
02
Drugs
octreotide
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on CTR20254378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254378.